NewsHLA-genome-edited iPS cell production contracted by Vision Care Inc.
Kyoto, Japan, 30 March, 2021 - The CiRA Foundation® ("CiRA_F"; located in Kyoto, Japan) today has signed an agreement with Vision Care Inc.("Vision Care"; located in Kobe, Japan) to manufacture HLA-genome-edited iPS cells for use in clinical research and clinical trials.
HLA-genome-edited iPS cells are iPS cells that have been gene edited to knock out the HLA gene, thus reducing the risk of immune rejection following transplantation of the cell product. This makes it possible to manufacture products from a single iPS cell that can be used for a larger number of patients instead of using products from iPS cells that match the patient's HLA.
Vision Care is engaged in research and development in the fields of ophthalmology and regenerative medicine at the Kobe Eye Center. President Masayo Takahashi is widely known for her research and development of iPS cell-derived retinal cells and directed the world's first human transplant of iPS cell products.
With the signing of this contract, CiRA_F and Vision Care expect to expand the number of diseases and subjects for transplantation.
The genome editing of iPS cells will be performed together with Vision Care in accordance with the standards for regenerative medicine products that Vision Care will independently produce.
We are also preparing to manufacture and stock HLA-genome-edited iPS cells for wide availability by 2022.
Finally, we will continue to cooperate with industry and academia to make regenerative medicine using iPS cells available to the medical community as soon as possible.